Skip to main content

Table 1 Characteristics of the study population stratified by chelation therapy

From: Combined sodium Dimercaptopropanesulfonate and zinc versus D-penicillamine as first-line therapy for neurological Wilson’s disease

  Group 1 (N = 93) Group 2 (N = 65) P value
Age (years) 24.47 ± 8.00 26.93 ± 8.16 0.062
Female (n, %) 33 (35.5%) 32 (49.2%) 0.084
Time since first symptoms (months) 24 (3–60) 23 (3–96) 0.748
Psychiatric symptoms (n, %) 5 (5.4%) 4 (6.1%) 0.836
Hepatic dysfunction at diagnosis (n, %) 23 (24.7%) 19 (29.2%) 0.529
Kayser-Fleischer corneal rings (n, %) 93 (100%) 65 (100%)  
Serum ceruloplasmin (< 200 mg/L) 93 (100%) 65 (100%)  
Abnormal brain MRI (n, %) 93 (100%) 65 (100%)  
  1. Group 1: treated by sodium 2, 3-dimercapto-1-propane sulfonate in combination of zinc; Group 2: treated by D-penicillamine; MRI: magnetic resonance imaging